INmune Bio and Quantum Computing Inc. (QCi) have announced a collaboration to apply quantum computing, artificial intelligence and conventional data analytics to identify new potential uses for XPro (XPro1595), INmune Bio's investigational treatment for Alzheimer's disease and other conditions. The Stage 1 engagement is QCi's first commercial customer in the pharmaceutical and biotechnology market, and the agreement includes options for additional work as INmune Bio advances its clinical programs.
The approach combines INmune Bio's data, drawn from pre-clinical research and four clinical trials, with clinical and publicly available biomedical datasets. The companies intend to look for relationships that could point to diseases driven by the same biology XPro targets, and then rank those diseases by their likelihood of success. XPro is designed to selectively inhibit soluble tumor necrosis factor (TNF), an inflammatory protein, while preserving other TNF functions important to the immune system. INmune Bio is investigating that targeted approach in neurological and rare diseases.
INmune Bio's chief executive framed rare diseases as a starting point because trials there can be smaller, faster and more capital-efficient, and because qualifying pediatric approvals may earn a Priority Review Voucher. The companies also say they want to identify patient populations and biomarkers most likely to predict response to treatment.
Part of the program is a direct test of the method itself. The companies plan to compare results from QCi's Dirac-3S quantum optimization machine with conventional statistical and machine-learning methods, to determine which approach works best for different parts of the analysis. The collaboration is also meant to build a repeatable discovery process that INmune Bio can reuse with other datasets and disease indications.
For INmune Bio, the work offers a way to judge the wider potential of XPro and set priorities for development. For QCi, it is a chance to show how its room-temperature, low-power quantum hardware can handle complex problems in drug research. The source material does not report any results from the collaboration yet, so the value of the approach remains to be demonstrated.